News articles about Mirati Therapeutics (NASDAQ:MRTX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.3878733655033 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s rankings:
- Mirati Therapeutics (MRTX) Upgraded by ValuEngine to “Buy” (americanbankingnews.com)
- Mirati Therapeutics (MRTX) Upgraded by Zacks Investment Research to “Hold” (americanbankingnews.com)
- Mirati Therapeutics’ (MRTX) Buy Rating Reiterated at HC Wainwright (americanbankingnews.com)
- Mirati Therapeutics (MRTX) PT Set at $18.00 by Oppenheimer (americanbankingnews.com)
- HC Wainwright Boosts Mirati Therapeutics (MRTX) Price Target to $21.00 (americanbankingnews.com)
Shares of Mirati Therapeutics stock traded up $0.40 on Wednesday, hitting $28.10. The company had a trading volume of 423,843 shares, compared to its average volume of 442,694. The company has a market cap of $827.69, a PE ratio of -10.11 and a beta of 2.15. Mirati Therapeutics has a 1 year low of $2.70 and a 1 year high of $37.62.
MRTX has been the topic of a number of recent analyst reports. ValuEngine raised Mirati Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. BidaskClub downgraded Mirati Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 29th. Zacks Investment Research downgraded Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th. HC Wainwright boosted their price objective on Mirati Therapeutics to $40.00 and gave the company a “buy” rating in a research note on Monday, March 12th. Finally, Barclays began coverage on Mirati Therapeutics in a research note on Monday, March 12th. They set an “overweight” rating and a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $25.44.
In other Mirati Therapeutics news, CFO Jamie A. Donadio sold 12,100 shares of the stock in a transaction on Friday, March 9th. The stock was sold at an average price of $35.00, for a total transaction of $423,500.00. Following the completion of the transaction, the chief financial officer now directly owns 12,100 shares of the company’s stock, valued at $423,500. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jamie A. Donadio sold 51,875 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $27.13, for a total value of $1,407,368.75. Following the transaction, the chief financial officer now directly owns 9,375 shares of the company’s stock, valued at $254,343.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 125,014 shares of company stock valued at $3,477,750. 5.10% of the stock is currently owned by corporate insiders.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.